|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM308573439 |
| 003 |
DE-627 |
| 005 |
20231225132022.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108414
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1028.xml
|
| 035 |
|
|
|a (DE-627)NLM308573439
|
| 035 |
|
|
|a (NLM)32272196
|
| 035 |
|
|
|a (PII)S1521-6616(20)30238-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Dal Moro, Fabrizio
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.10.2020
|
| 500 |
|
|
|a Date Revised 07.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 650 |
|
4 |
|a Letter
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a Phosphodiesterase 5 Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Nitric Oxide
|2 NLM
|
| 650 |
|
7 |
|a 31C4KY9ESH
|2 NLM
|
| 700 |
1 |
|
|a Livi, Ugolino
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 214(2020) vom: 01. Mai, Seite 108414
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:214
|g year:2020
|g day:01
|g month:05
|g pages:108414
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108414
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 214
|j 2020
|b 01
|c 05
|h 108414
|